SubHero Banner

Synjardy® XR (empagliflozin/metformin extended-release) – New Formulation Approval

December 12, 2016 – Eli Lilly and Boehringer-Ingelheim announced the FDA approval of Synjardy XR (empagliflozin/metformin extended-release), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate. 

Download PDF